Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

NCT03700905 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

276

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

PROCEDURE: Surgical resection of primary tumor
RADIATION: Adjuvant radio(-chemo)therapy
DRUG: Neoadjuvant Nivolumab
DRUG: Adjuvant Nivolumab
DRUG: Adjuvant Nivolumab and Ipilimumab

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Collaborators

[object Object]
[object Object]
[object Object]